Categories Earnings, Finance

Earnings Summary: A snapshot of Cboe Global’s (CBOE) Q3 2025 report

Financial services company Cboe Global Markets, Inc. (CBOE: CBOE) on Friday reported financial results for the third quarter of fiscal 2025.

  • Third-quarter earnings per share increased 38% year-over-year to a record high of $2.85
  • On an adjusted basis, earnings climbed 20% annually to $2.67 per share, an all-time high
  • At $605.5 million, September-quarter revenue was up14% YoY, which is the highest ever recorded by the company
  • The management increased its full-year 2025 organic total revenue growth target to low double-digit to mid-teens from high single-digit
  • It also raised Cboe Data Vantage organic revenue growth guidance for FY25 to high single-digit to low double-digit from mid to high single-digit
  • Full-year adjusted operating expense target has been reduced to $827-842 million, from the previous forecast in the range of $832 million to $847 million

Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.

Most Popular

AVGO Earnings: Broadcom reports higher Q4 FY25 revenue, profit; results beat

Semiconductor company Broadcom, Inc. (NASDAQ: AVGO) on Thursday reported an increase in revenue and adjusted earnings for the fourth quarter of fiscal 2025. The numbers also surpassed analysts' expectations. Adjusted

Unicycive is all-in on kidney care, focusing on underserved areas: CEO

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a biotech firm engaged in the development of novel treatment options for patients with renal diseases. In an email interview with AlphaStreet, CEO Dr.

Lamb Weston (LW) is set to report Q2 2026 earnings next week, here’s what to look for

Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose over 1% on Thursday. The stock has gained 4% over the past three months. The French fry giant is slated to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top